On May 9, Ma Yinglong (600993) announced that the company signed a “strategic cooperation framework agreement” with BGI (300676) on the same day in Shenzhen. The agreement includes: 1. Research and application of intestinal flora; 2. Diagnosis and treatment of anorectal and lower digestive tract diseases; 3. Construction of a dynamic database of meta metagenomic data, clinical phenotypic data, and meta metagenome of intestinal microflora during intestinal conditioning in Chinese anorectal diseases. The announcement said the signing of this agreement is conducive to the cooperation between the two parties to achieve complementary advantages and resource sharing and will jointly promote the achievement transformation and application of genomics in the anorectal health field, promote the development of gene technology in the anorectal health industry, and serve people's health. It will help the company improve the anorectal health business ecosystem, provide customers with professional, personalized and diversified anorectal health management programs, and promote the company's transformation and upgrading to an anorectal health provider.
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
